产品编号 :
Cas No. :
| 包装规格 | 纯度 | 目录价 | 会员专享价 | 库存 | 数量 |
|---|---|---|---|---|---|
| 25mg | 98% | 现货 | |||
| 50mg | 98% | 现货 | |||
| 100mg | 98% | 现货 | |||
| 250mg | 98% | 现货 |
| 包装规格 | 纯度 | 目录价 | 会员专享价 | 库存 | 数量 |
|---|---|---|---|---|---|
| 25mg | 98% | 现货 | |||
| 50mg | 98% | 现货 | |||
| 100mg | 98% | 现货 | |||
| 250mg | 98% | 现货 |
CAS No. |
375835-43-1 |
|---|---|
中文名称 |
2-((3-氰基-6-氧代-4-(对甲苯基)-1,4,5,6-四氢吡啶-2-基)硫基)-N-(噻唑-2-基)乙酰胺 |
英文名称 |
2-((3-Cyano-6-oxo-4-(p-tolyl)-1,4,5,6-tetrahydropyridin-2-yl)thio)-N-(thiazol-2-yl)acetamide |
别名 |
2-{[3-cyano-4-(4-methylphenyl)-6-oxo-1,4,5,6-tetrahydropyridin-2-yl]sulfanyl}-N-(1,3-thiazol-2-yl)acetamide;nec-34;Necrostatin-34;2-{[3-cyano-4-(4-methylphenyl)-6-oxo-1,4;2-((3-Cyano-6-oxo-4-(p-tolyl)-1,4,5,6-tetrahydropyridin-2-yl)thio)-N-(thiazol-2-yl)acetamide;Necrostatin 34,RIP kinase,FADD,Necrostatin-34,RIPK,inhibit,RIPK1,Receptor-interacting protein kinases,p-S166,Necroptosis,Necrostatin34,Inhibitor;Acetamide, 2-[[3-cyano-1,4,5,6-tetrahydro-4-(4-methylphenyl)-6-oxo-2-pyridinyl]thio]-N-2-thiazolyl-;Necrostatin-34, 10 mM in DMSO |
标准英文名 |
2-((3-cyano-6-oxo-4-(p-tolyl)-1,4,5,6-tetrahydropyridin-2-yl)thio)-N-(thiazol-2-yl)acetamide |
MDL No. |
MFCD02241236 |
分子式 |
C18H16N4O2S2 |
分子量 |
384.49 |
精确分子量 |
384.07 |
SMILES |
O=C(NC1=NC=CS1)CSC2=C(C#N)C(C3=CC=C(C)C=C3)CC(N2)=O |
标准SMILES |
CC1C=CC(=CC=1)C1CC(=O)NC(SCC(=O)NC2=NC=CS2)=C1C#N |
性状 |
Solid |
用途 |
For laboratory research purposes. Not for drug or household use. |
信号词 |
Warning |
InChIKey |
LOQIRQHGJVGIEL-UHFFFAOYSA-N |
危险类别(旧) |
H302 |
存储要求 |
Sealed in dry, 2-8°C,Keep container tightly closed in a dry and well-ventilated area. Containers which are opened must be carefully resealed and kept upright to prevent leakage. |
危险品分类 |
Acute toxicity, oral (Category 4),Skin corrosion/irritation (Category 2),Serious eye damage/eye irritation (Category 2A),Specific target organ toxicity, single exposure; Respiratory system (Category 3) |
|---|---|
化学稳定性 |
Stable under recommended storage conditions. |
符号 |
|
|
|
评论 |
|---|